SOPHiA GENETICS

SOPH

Market cap $211M

Overview Fund Activity

3.12 USD

-0.08

2.5%

At close Updated Sep 12, 4:00 PM EDT

1 day

-2.5%

5 days

-5.45%

1 month

-0.64%

3 months

7.59%

6 months

-5.45%

Year to date

-2.19%

1 year

-20%

5 years

-81.38%

10 years

-81.38%

About: Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.

Employees: 423

Healthcare Health Information Services

0

Funds holding %

of 7,462 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

38% more repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 8

0% more funds holding

Funds holding: 32 [Q1] → 32 (+0) [Q2]

0% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 6

10.01% less ownership

Funds ownership: 34.79% [Q1] → 24.78% (-10.01%) [Q2]

34% less capital invested

Capital invested by funds: $77.2M [Q1] → $51.2M (-$26M) [Q2]

100% less funds holding in top 10

Funds holding in top 10: 1 [Q1] → 0 (-1) [Q2]

See Fund Rankings

Financial journalist opinion

SOPHiA GENETICS and Jessa Ziekenhuis Announce Precision Oncology Partnership from the European Congress of Pathology

BOSTON and ROLLE, Switzerland , Sept. 5, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, has announced a significant new collaboration with Jessa Ziekenhuis in Hasselt, Belgium.

SOPHiA GENETICS and Jessa Ziekenhuis Announce Precision Oncology Partnership from the European Congress of Pathology

SOPHiA GENETICS SA (SOPH) Q2 2025 Earnings Call Transcript

SOPHiA GENETICS SA (NASDAQ:SOPH ) Q2 2025 Earnings Conference Call August 5, 2025 8:00 AM ET Company Participants George A. Cardoza - Executive VP & CFO Jurgi Camblong - Co-Founder, CEO & Director Kellen Sanger - Head of Strategy and Investor Relations Ross Jordan Muken - President Conference Call Participants Conor Noel McNamara - RBC Capital Markets, Research Division Daniel Gregory Brennan - TD Cowen, Research Division Subhalaxmi T.

SOPHiA GENETICS SA (SOPH) Q2 2025 Earnings Call Transcript

SOPHiA GENETICS Reports Second Quarter 2025 Results

BOSTON and ROLLE, Switzerland, Aug. 5, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and leader in data-driven medicine, today reported financial results for the second quarter ended June 30, 2025. Second Quarter 2025 Financial Results Revenue was $18.3 million, up 16% year-over-year Gross margin was 67.0% on a reported basis and 74.4% on an adjusted basis, up from 68.2% reported and 73.2% adjusted in the prior year period IFRS net loss increased 48% year-over-year to $22.4 million (or 23% excluding foreign exchange impact); Adjusted EBITDA loss increased 33% to $11.7 million; Cash burn improved 35% to $8.7 million (or 10% excluding foreign exchange impact) The company reiterates full-year guidance of revenue between $72 million and $76 million and adjusted EBITDA loss between $35 million and $39 million "We delivered another strong quarter of revenue growth in Q2 with 16% year-over-year growth, as new business continues to ramp and transformative applications like MSK-ACCESS® powered with SOPHiA DDMTM gain adoption," said Jurgi Camblong, PhD.

SOPHiA GENETICS Reports Second Quarter 2025 Results

SOPHiA GENETICS expands collaboration with AstraZeneca using AI to improve breast cancer patient outcomes

BOSTON and ROLLE, Switzerland , Aug. 5, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced an expansion of its partnership with AstraZeneca (LSE/STO/Nasdaq: AZN). This new, multi-year collaboration will leverage SOPHiA GENETICS's multimodal AI Factories to generate evidence on the efficacy, value, and real-world impact of therapies for certain types of breast cancer.

SOPHiA GENETICS expands collaboration with AstraZeneca using AI to improve breast cancer patient outcomes

SOPHiA GENETICS to Announce Financial Results for Second Quarter 2025 on August 5, 2025

BOSTON and ROLLE, Switzerland , July 22, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced it will release its financial results for the second quarter 2025 before U.S. markets open on Tuesday, August 5, 2025. On that day, SOPHiA GENETICS will host a conference call to discuss its financial results as well as business outlook beginning at 8:00 a.m.

SOPHiA GENETICS to Announce Financial Results for Second Quarter 2025 on August 5, 2025

SOPHiA GENETICS SA (SOPH) Q1 2025 Earnings Call Transcript

SOPHiA GENETICS SA. (NASDAQ:SOPH ) Q1 2025 Earnings Conference Call May 6, 2025 8:00 AM ET Company Participants Kellen Sanger - Head, Strategy and Investor Relations Jurgi Camblong - Co-Founder and Chief Executive Officer Ross Muken - President George Cardoza - Chief Financial Officer Conference Call Participants William Bonello - Craig-Hallum Conor McNamara - RBC Capital Markets Subbu Nambi - Guggenheim Operator Good morning, ladies and gentlemen, and welcome to the SOPHiA GENETICS Q1 2025 Earnings Call.

SOPHiA GENETICS SA (SOPH) Q1 2025 Earnings Call Transcript

Zacks Investment Research

SOPHiA GENETICS SA (SOPH) Reports Q1 Loss, Tops Revenue Estimates

SOPHiA GENETICS SA (SOPH) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to loss of $0.21 per share a year ago.

SOPHiA GENETICS SA (SOPH) Reports Q1 Loss, Tops Revenue Estimates

SOPHiA GENETICS Reports First Quarter 2025 Results

BOSTON and ROLLE, Switzerland , May 6, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and leader in data-driven medicine, today reported financial results for the first quarter ended March 31, 2025. First Quarter 2025 Financial Results Revenue was $17.8 million, up 13% year-over-year or 15% on a constant currency basis Gross margin was 68.7% on a reported basis and 75.7% on an adjusted basis, up from 65.9% and 70.5% in the prior year period, respectively IFRS net loss increased 27% year-over-year to $17.4 million (including a net foreign exchange P&L impact of $5.2 million), and adjusted EBITDA loss improved 24% year-over-year to $9.8 million The company reiterates full-year guidance of revenue between $72 million and $76 million and adjusted EBITDA loss between $35 million and $39 million "We started the year strong with year-over-year revenue growth of 13%, or 15% on a constant currency basis, as the large amount of new business signed in 2024 begins to ramp," said Jurgi Camblong, PhD.

SOPHiA GENETICS Reports First Quarter 2025 Results

SOPHiA GENETICS Announces Expanded Collaboration with AstraZeneca to Accelerate Liquid Biopsy Testing Globally from AACR

BOSTON and ROLLE, Switzerland , April 28, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and global leader in data-driven medicine, today announced the expansion of its ongoing collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN) to accelerate the deployment of MSK-ACCESS® powered with SOPHiA DDM™ globally. Building on the initial collaboration announced in October 2024 , this new phase will extend the test's reach to a total of 30 clinical institutions worldwide in 2025.

SOPHiA GENETICS Announces Expanded Collaboration with AstraZeneca to Accelerate Liquid Biopsy Testing Globally from AACR

SOPHiA GENETICS to Announce Financial Results for First Quarter 2025 on May 6, 2025

BOSTON and ROLLE, Switzerland , April 22, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced it will release its financial results for the first quarter 2025 before U.S. markets open on Tuesday, May 6, 2025. On that day, SOPHiA GENETICS will host a conference call to discuss its financial results as well as business outlook beginning at 8:00 a.m.

SOPHiA GENETICS to Announce Financial Results for First Quarter 2025 on May 6, 2025

See News Rankings

Charts implemented using Lightweight Charts™